Results 111 to 120 of about 53,685 (285)

Patient Selection in Deep Brain Stimulation: A Role for Transcranial Direct Current Stimulation to Enhance the Levodopa Challenge?

Annals of Clinical and Translational Neurology
Dopaminergic medication and deep brain stimulation (DBS) improve motor symptoms in Parkinson's disease (PD), but levodopa response alone may not predict DBS outcomes.
Lukas L. Goede, Patricia Zvarova, Bahne H. Bahners, Andreas Horn   +3 more
doaj   +1 more source

Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers

, 2013
OBJECTIVES:An oral dispersible microtablet formulation of levodopa/carbidopa 5/1.25 mg (LC-5) was developed for individualized repeated dosing. The aim was to compare pharmacokinetic profiles of LC-5 and levodopa/carbidopa/entacapone (LCE).MATERIALS AND ...
Spira, J, Nyholm, D, Nyström, C, Lewander, T, Nyholm, Dag,, Aquilonius, Sten-Magnus,, Lewander, Tommy,, Ehrnebo, M, Aquilonius, S-M, Panagiotidis, G, Trolin, CG, Bäckström, T, Trolin, C G   +12 more
core   +1 more source

Continuous Subcutaneous Apomorphine as a Temporary Bridging Therapy for Dopamine Dysregulation Syndrome in Patients with Deep Brain Stimulation [PDF]

Mov Disord Clin Pract
Abstract Background Dopamine dysregulation syndrome (DDS) is a challenging complication of dopaminergic therapy in Parkinson's disease and can persist despite subthalamic deep brain stimulation (STN‐DBS). We evaluated a temporary bridging concept in which oral dopaminergic medication was replaced by continuous subcutaneous apomorphine infusion while ...
Binder T, Hartig J, Sitzmann L, Ip C, Capetian P, Lange F, Reich M, Daniels C, Volkmann J.   +8 more
europepmc   +2 more sources

Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address ...
Saar Anis, Omer Anis, Abhishek Lenka, Junaid H. Siddiqui   +3 more
wiley   +1 more source

Highly efficient electrocatalytic oxidation of levodopa as a Parkinson therapeutic drug based on modified screen-printed electrode

Heliyon
The current study presents the creation of a straightforward and sensitive sensor based on ZnO/Co3O4 nanocomposite modified screen-printed electrode (ZnO/Co3O4NC/SPE) for levodopa determination. At ZnO/Co3O4NC/SPE, an oxidative peak for levodopa solution
Tan Wang, Nadhir N.A. Jafar, Afrah Majeed Ahmed Al-Rihaymee, Dheyaa Yahaia Alhameedi, Fadhil A. Rasen, Furqan S. Hashim, Talib Kh Hussein, Montather F. Ramadan, Kasim Kadhim Alasedi, Muath Suliman, Ahmed Hussien Alawadi   +10 more
doaj   +1 more source

Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Freezing of gait (FoG) belongs to most pressing unmet symptoms in the treatment of Parkinson's disease. Objectives To explore whether combined subthalamic and nigral (STN + SNr) deep brain stimulation improves FoG compared with optimized STN stimulation alone; to identify clinical variables associated with therapeutic response ...
Daniel Weiss, Idil Cebi, Marion Schütt, Imma Fischer, Lukas Pavelka, Pierre Kolber, Monika Pötter‐Nerger, Wolfgang Hamel, Andrea A. Kühn, Christian J. Hartmann, Kai Bötzel, Thomas Köglsperger, Michael T. Barbe, Zacharias Kohl, Steffen Paschen, Markus A. Hobert, Sergiu Groppa, Tobias Warnecke, Inga Claus, Rejko Krüger, Alireza Gharabaghi, For the Multicenter STN+SNr Study Group, Christian Stallinger, Frank Hertel, Daniel Kroneberg, Carsten Buhmann, Alessandro Gulberti, Beate Schönewald, Verena Zentsch, Verle Visser‐Vandewalle   +29 more
wiley   +1 more source

Through the body into the brain: The pathway of Levodopa in Parkinson's disease

reservedLa Levodopa rappresenta da sempre il trattamento farmacologico di base adoperato al fine di gestire e contrastare la progressione sintomatica della malattia di Parkinson.
D'AUGUSTA PERNA, CHIARA
core  

JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?

Movement Disorders Clinical Practice, EarlyView.
Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado, Koustubh Bavdhankar, Divyani Garg, Francesca Magrinelli, Huw R. Morris, Kailash P. Bhatia   +5 more
wiley   +1 more source

Effects of Bromocriptine on Dopamine Turnover with or without Levodopa

, 1996
Bromocriptine, a dopamine agonist, alleviates symptoms of Parkinson's disease, even when administered alone, and is used for its treatment. Better therapeutic effects are, however, achieved when bromocriptine is used in combination with levodopa.
M Asanvma, K Matsuura, K Iida, M Yamamoto, K Tanaka, N Ogawa   +5 more
core   +1 more source

Neuropsychiatric‐Led Presentation of Late‐Onset Parkin‐Related Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sarah Fullam, Shane Lyons, Martha Finnegan, Richard Walsh, Sean O'Dowd   +4 more
wiley   +1 more source